CAR-T (Allogeneic)
Memory NK (Allogeneic)
-- First Pivotal Trial for an Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell Therapy to Begin in First Quarter 2025 -- --…
ST. LOUIS, MO and SAN DIEGO, CA, Nov. 12, 2024 – Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf…
-- Researchers Shared Findings Including a Clinically Manageable Safety Profile and Anti-leukemic Activity with WU-CART-007 in Patients with R/R T-ALL/LBL…
Wugen is a clinical-stage biotechnology company
Cellular therapies originating from healthy donors
Come join our growing teams in San Diego and St. Louis